Physician profile
Ajay Kumar
NPI 1851777577
$2,544.10
in general payments reported to CMS, 2019-2025
24 companies · $772 in 2025
The $772 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.82 · 2020: $24.83 · 2022: $18.75 · 2023: $529 · 2024: $1,120 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,344 · Long Term Medical Supply Or Device Loan: $39.96 · Education: $37.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,344.04 |
| Long Term Medical Supply Or Device Loan | $39.96 |
| Education | $37.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $358.66 | 2019-2025 | Evenity, Prolia, Repatha |
| Insulet Corporation | $290.23 | 2024-2025 | Omnipod |
| Abbott Laboratories | $259.85 | 2024-2025 | Freestyle Libre 3, Freestyle Libre, Freestyle Insulinx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.98 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Novo Nordisk INC | $224.96 | 2019-2025 | Ozempic, Rybelsus |
| Alexion Pharmaceuticals, INC. | $204.53 | 2023-2024 | Strensiq |
| Xeris Pharmaceuticals, INC. | $131.74 | 2023-2024 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $131.00 | 2025 | |
| Abbvie INC. | $108.69 | 2022-2025 | |
| Radius Health, INC. | $91.60 | 2023-2024 | Tymlos |
| Sanofi-Aventis U.S. LLC | $72.87 | 2023-2025 | |
| Astellas Pharma US INC | $68.08 | 2023-2025 | Veozah |
| Lundbeck LLC | $51.42 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $50.35 | 2023-2024 | |
| Corcept Therapeutics | $44.67 | 2024 | Korlym |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $40.51 | 2024-2025 | Mounjaro, Zepbound |
| Ascendis Pharma Endocrinology INC | $38.05 | 2025 | Yorvipath |
| Medtronic, INC. | $32.07 | 2024-2025 | Minimed 780g |
| Recordati_rare_diseases_inc. | $21.17 | 2025 | Isturisa |
| Beta Bionics, INC. | $18.72 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Bayer Healthcare Pharmaceuticals INC. | $17.96 | 2025 | |
| Exact Sciences Corporation | $16.13 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $13.33 | 2020 | |
| Cequr Corporation | $10.53 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.